Susan Pyne

List of Publications by Year
in descending order

166 papers	10,654 citations	34493 54 h-index	40945 97 g-index
171 all docs	171 docs citations	171 times ranked	10110 citing authors

#	Article	IF	Citations
1	Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti-fibrotic treatment options in a mouse model of tubulointerstitial fibrosis. Cellular Signalling, 2021, 79, 109881.	1.7	7
2	A new model for regulation of sphingosine kinase 1 translocation to the plasma membrane in breast cancer cells. Journal of Biological Chemistry, 2021, 296, 100674.	1.6	2
3	Dihydroceramide Desaturase Functions as an Inducer and Rectifier of Apoptosis: Effect of Retinol Derivatives, Antioxidants and Phenolic Compounds. Cell Biochemistry and Biophysics, 2021, 79, 461-475.	0.9	6
4	Interleukin-7 receptor Î± mutational activation can initiate precursor B-cell acute lymphoblastic leukemia. Nature Communications, 2021, 12, 7268.	5.8	24
5	Structure-function analysis of lipid substrates and inhibitors of sphingosine kinases. Cellular Signalling, 2020, 76, 109806.	1.7	10
6	A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of NaÃ¯ve CD4 T Lymphocytes. International Journal of Molecular Sciences, 2020, 21, 8371.	1.8	12
7	Recent advances in the role of sphingosine 1â€phosphate in cancer. FEBS Letters, 2020, 594, 3583-3601.	1.3	35
8	Translational pharmacology of an inhaled small molecule Î±vÎ²6 integrin inhibitor for idiopathic pulmonary fibrosis. Nature Communications, 2020, 11, 4659.	5.8	65
9	The regulation of p53, p38 MAPK, JNK and XBP-1s by sphingosine kinases in human embryonic kidney cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158631.	1.2	1
10	Sphingosine Kinase 1 Regulates the Survival of Breast Cancer Stem Cells and Non-stem Breast Cancer Cells by Suppression of STAT1. Cells, 2020, 9, 886.	1.8	23
11	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology, 2019, 176, S297-S396.	2.7	423
12	Topographical Mapping of Isoform-Selectivity Determinants for J-Channel-Binding Inhibitors of Sphingosine Kinases 1 and 2. Journal of Medicinal Chemistry, 2019, 62, 3658-3676.	2.9	23
13	Ceramide and sphingosine 1-phosphate in adipose dysfunction. Progress in Lipid Research, 2019, 74, 145-159.	5.3	30
14	Short Periods of Hypoxia Upregulate Sphingosine Kinase 1 and Increase Vasodilation of Arteries to Sphingosine 1-Phosphate (S1P) via S1P₃. Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 63-74.	1.3	8
15	Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse. European Journal of Pharmacology, 2019, 842, 1-9.	1.7	9
16	Sphingosine Kinases as Druggable Targets. Handbook of Experimental Pharmacology, 2018, 259, 49-76.	0.9	12
17	Sphingosine 1-phosphate and cancer. Advances in Biological Regulation, 2018, 68, 97-106.	1.4	82
18	Does the Sphingosine 1-Phosphate Receptor-1 Provide a Better or Worse Prognostic Outcome for Breast Cancer Patients?. Frontiers in Oncology, 2018, 8, 417.	1.3	0

#	Article	IF	Citations
19	Native and Polyubiquitinated Forms of Dihydroceramide Desaturase Are Differentially Linked to Human Embryonic Kidney Cell Survival. Molecular and Cellular Biology, 2018, 38, .	1.1	16
20	The sphingosine 1-phosphate receptor 2 is shed in exosomes from breast cancer cells and is N-terminally processed to a short constitutively active form that promotes extracellular signal regulated kinase activation and DNA synthesis in fibroblasts. Oncotarget, 2018, 9, 29453-29467.	0.8	27
21	Sphingosine Kinase 2 in Autoimmune/Inflammatory Disease and the Development of Sphingosine Kinase 2 Inhibitors. Trends in Pharmacological Sciences, 2017, 38, 581-591.	4.0	34
22	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview. British Journal of Pharmacology, 2017, 174, S1-S16.	2.7	269
23	Sphingosine Kinase 1: A Potential Therapeutic Target in Pulmonary Arterial Hypertension?. Trends in Molecular Medicine, 2017, 23, 786-798.	3.5	23
24	Effect of sphingosine kinase modulators on interleukinâ€1Î² release, sphingosine 1â€phosphate receptor 1 expression and experimental autoimmune encephalomyelitis. British Journal of Pharmacology, 2017, 174, 210-222.	2.7	8
25	Sphingosine 1-Phosphate Receptor 1 Signaling in Mammalian Cells. Molecules, 2017, 22, 344.	1.7	64
26	Sphingosine kinase 2 and multiple myeloma. Oncotarget, 2017, 8, 43596-43597.	0.8	3
27	Pharmacological Characterization of the Î±vÎ²6 Integrin Binding and Internalization Kinetics of the Foot-and-Mouth Disease Virus Derived Peptide A20FMDV2. Pharmacology, 2016, 97, 114-125.	0.9	26
28	Effect of the sphingosine kinase 1 selective inhibitor, PF-543 on arterial and cardiac remodelling in a hypoxic model of pulmonary arterial hypertension. Cellular Signalling, 2016, 28, 946-955.	1.7	37
29	Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. Leukemia, 2016, 30, 2142-2151.	3.3	34
30	Sphingosine Kinases: Emerging Structureâ€"Function Insights. Trends in Biochemical Sciences, 2016, 41, 395-409.	3.7	62
31	Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances. Progress in Lipid Research, 2016, 62, 93-106.	5.3	153
32	Effect of ether glycerol lipids on interleukin-1Î² release and experimental autoimmune encephalomyelitis. Chemistry and Physics of Lipids, 2016, 194, 2-11.	1.5	4
33	Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation. Advances in Biological Regulation, 2016, 60, 151-159.	1.4	119
34	Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells. Oncotarget, 2016, 7, 16663-16675.	0.8	66
35	Resveratrol and its oligomers: modulation of sphingolipid metabolism and signaling in disease. Archives of Toxicology, 2014, 88, 2213-2232.	1.9	16
36	Sphingosine kinase 1 enables communication between melanoma cells and fibroblasts that provides a new link to metastasis. Oncogene, 2014, 33, 3361-3363.	2.6	9

#	Article	IF	Citations
37	The role of sphingosine 1-phosphate in inflammation and cancer. Advances in Biological Regulation, 2014, 54, 121-129.	1.4	44
38	Crystal Structure of Sphingosine Kinase 1 with PF-543. ACS Medicinal Chemistry Letters, 2014, 5, 1329-1333.	1.3	90
39	Sphingosine kinase 2 prevents the nuclear translocation of sphingosine 1-phosphate receptor-2 and tyrosine 416 phosphorylated c-Src and increases estrogen receptor negative MDA-MB-231 breast cancer cell growth: The role of sphingosine 1-phosphate receptor-4. Cellular Signalling, 2014, 26, 1040-1047.	1.7	23
40	Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. Oncotarget, 2014, 5, 7886-7901.	0.8	36
41	Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1â€phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptorâ€positive breast cancer. International Journal of Cancer, 2013, 132, 605-616.	2.3	40
42	Sphingosine 1-Phosphate Is a Missing Link between Chronic Inflammation and Colon Cancer. Cancer Cell, 2013, 23, 5-7.	7.7	29
43	New Perspectives on the Role of Sphingosine 1-Phosphate in Cancer. Handbook of Experimental Pharmacology, 2013, , 55-71.	0.9	20
44	Structureâ€“Activity Relationships and Molecular Modeling of Sphingosine Kinase Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 9310-9327.	2.9	43
45	The sphingosine kinase inhibitor 2â€(<i>p</i>â€hyroxyanilino)â€4â€(<i>p</i>â€chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stressâ€dependent mechanism. British Journal of Pharmacology, 2013, 168, 1497-1505.	2.7	16
46	Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells. MedChemComm, 2013, 4, 1394.	3.5	53
47	Synthesis of selective inhibitors of sphingosine kinase 1. Chemical Communications, 2013, 49, 2136.	2.2	52
48	The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells. Cellular Signalling, 2013, 25, 1011-1017.	1.7	46
49	Synthesis of (S)-FTY720 vinylphosphonate analogues and evaluation of their potential as sphingosine kinase 1 inhibitors and activators. Bioorganic and Medicinal Chemistry, 2013, 21, 2503-2510.	1.4	23
50	Lipid phosphate phosphatase 3 participates in transport carrier formation and protein trafficking in the early secretory pathway. Journal of Cell Science, 2013, 126, 2641-55.	1.2	32
51	Role of sphingosine 1-phosphate and lysophosphatidic acid in fibrosis. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2013, 1831, 228-238.	1.2	54
52	The Roles of Sphingosine Kinase 1 and 2 in Regulating the Metabolome and Survival of Prostate Cancer Cells. Biomolecules, 2013, 3, 316-333.	1.8	13
53	Regulation of cell survival by sphingosine-1-phosphate receptor S1P1 via reciprocal ERK-dependent suppression of Bim and PI-3-kinase/protein kinase C-mediated upregulation of Mcl-1. Cell Death and Disease, 2013, 4, e927-e927.	2.7	74
54	Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. British Journal of Cancer, 2012, 106, 1453-1459.	2.9	59

#	Article	IF	Citations
55	Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers. Frontiers in Oncology, 2012, 2, 168.	1.3	37
56	Lysolipids: Sphingosine 1-phosphate and lysophosphatidic acid. , 2012, , 85-106.		0
57	Resveratrol dimers are novel sphingosine kinase 1 inhibitors and affect sphingosine kinase 1 expression and cancer cell growth and survival. British Journal of Pharmacology, 2012, 166, 1605-1616.	2.7	54
58	Targeting sphingosine kinase 1 in cancer. Advances in Biological Regulation, 2012, 52, 31-38.	1.4	37
59	Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: Functional differences between sphingosine kinase 1a and 1b. International Journal of Biochemistry and Cell Biology, 2012, 44, 1457-1464.	1.2	36
60	Sphingosine 1-phosphate signalling in cancer. Biochemical Society Transactions, 2012, 40, 94-100.	1.6	109
61	Translational aspects of sphingosine 1-phosphate biology. Trends in Molecular Medicine, 2011, 17, 463-472.	3.5	66
62	Receptor tyrosine kinaseâ€“G-protein-coupled receptor signalling platforms: out of the shadow?. Trends in Pharmacological Sciences, 2011, 32, 443-450.	4.0	105
63	Selectivity and Specificity of Sphingosine 1-Phosphate Receptor Ligands: â€œOff-Targetsâ€•or Complex Pharmacology?. Frontiers in Pharmacology, 2011, 2, 26.	1.6	32
64	(R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells. Cellular Signalling, 2011, 23, 1590-1595.	1.7	95
65	Sphingosine Kinase Inhibitors and Cancer: Seeking the Golden Sword of Hercules. Cancer Research, 2011, 71, 6576-6582.	0.4	77
66	FTY720 Analogues as Sphingosine Kinase 1 Inhibitors. Journal of Biological Chemistry, 2011, 286, 18633-18640.	1.6	107
67	Intracellular S1P Generation Is Essential for S1P-Induced Motility of Human Lung Endothelial Cells: Role of Sphingosine Kinase 1 and S1P Lyase. PLoS ONE, 2011, 6, e16571.	1.1	49
68	FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cellular Signalling, 2010, 22, 1536-1542.	1.7	169
69	The sphingosine kinase inhibitor <i>N</i>,<i>N</i>â€•dimethylsphingosine inhibits neointimal hyperplasia. British Journal of Pharmacology, 2010, 159, 543-553.	2.7	12
70	Interaction between anandamide and sphingosineâ€•1â€•phosphate in mediating vasorelaxation in rat coronary artery. British Journal of Pharmacology, 2010, 161, 176-192.	2.7	30
71	Sphingosine Kinase 1 Induces Tolerance to Human Epidermal Growth Factor Receptor 2 and Prevents Formation of a Migratory Phenotype in Response to Sphingosine 1-Phosphate in Estrogen Receptor-Positive Breast Cancer Cells. Molecular and Cellular Biology, 2010, 30, 3827-3841.	1.1	94
72	Sphingosine 1-Phosphate Receptor 4 Uses HER2 (ERBB2) to Regulate Extracellular Signal Regulated Kinase-1/2 in MDA-MB-453 Breast Cancer Cells. Journal of Biological Chemistry, 2010, 285, 35957-35966.	1.6	72

#	Article	IF	Citations
73	Sphingosine 1-phosphate and cancer. Nature Reviews Cancer, 2010, 10, 489-503.	12.8	765
74	High Expression of Sphingosine 1-Phosphate Receptors, S1P1 and S1P3, Sphingosine Kinase 1, and Extracellular Signal-Regulated Kinase-1/2 Is Associated with Development of Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Patients. American Journal of Pathology, 2010, 177, 2205-2215.	1.9	156
75	The Sphingosine Kinase 1 Inhibitor 2-(p-Hydroxyanilino)-4-(p-chlorophenyl)thiazole Induces Proteasomal Degradation of Sphingosine Kinase 1 in Mammalian Cells*. Journal of Biological Chemistry, 2010, 285, 38841-38852.	1.6	106
76	Sphingosine 1-Phosphate Regulation of Extracellular Signal-Regulated Kinase-1/2 in Embryonic Stem Cells. Stem Cells and Development, 2009, 18, 1319-1330.	1.1	41
77	Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate signalling in health and disease. Cellular Signalling, 2009, 21, 14-21.	1.7	124
78	The sphingosine 1-phosphate receptor 5 and sphingosine kinases 1 and 2 are localised in centrosomes: Possible role in regulating cell division. Cellular Signalling, 2009, 21, 675-684.	1.7	30
79	The sigma1 receptor interacts with N-alkyl amines and endogenous sphingolipids. European Journal of Pharmacology, 2009, 609, 19-26.	1.7	77
80	New aspects of sphingosine 1-phosphate signaling in mammalian cells. Advances in Enzyme Regulation, 2009, 49, 214-221.	2.9	28
81	Targeting sphingosine-1-phosphate signalling for cardioprotection. Current Opinion in Pharmacology, 2009, 9, 194-201.	1.7	40
82	Sphingosine 1-phosphate, lysophosphatidic acid and growth factor signaling and termination. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 467-476.	1.2	34
83	Inhibition of non-Ras protein farnesylation reduces in-stent restenosis. Atherosclerosis, 2008, 197, 515-523.	0.4	13
84	Lipid phosphate phosphatases form homo- and hetero-oligomers: catalytic competency, subcellular distribution and function. Biochemical Journal, 2008, 411, 371-377.	1.7	23
85	Characterization of Salmonella typhimurium YegS, a putative lipid kinase homologous to eukaryotic sphingosine and diacylglycerol kinases. Proteins: Structure, Function and Bioinformatics, 2007, 68, 13-25.	1.5	20
86	Receptor tyrosine kinase-G-protein coupled receptor complex signaling in mammalian cells. Advances in Enzyme Regulation, 2007, 47, 271-280.	2.9	26
87	Lipid phosphate phosphatase-1 regulates lysophosphatidic acid- and platelet-derived-growth-factor-induced cell migration. Biochemical Journal, 2006, 394, 495-500.	1.7	29
88	Integrin signalling regulates the nuclear localization and function of the lysophosphatidic acid receptor-1 (LPA1) in mammalian cells. Biochemical Journal, 2006, 398, 55-62.	1.7	32
89	Protean agonism of the lysophosphatidic acid receptor-1 with Ki16425 reduces nerve growth factor-induced neurite outgrowth in pheochromocytoma 12 cells. Journal of Neurochemistry, 2006, 98, 1920-1929.	2.1	24
90	The effect of RGS12 on PDGFÎ² receptor signalling to p42/p44 mitogen activated protein kinase in mammalian cells. Cellular Signalling, 2006, 18, 971-981.	1.7	39

#	Article	IF	Citations
91	The effect of hypoxia on lipid phosphate receptor and sphingosine kinase expression and mitogen-activated protein kinase signaling in human pulmonary smooth muscle cells. Prostaglandins and Other Lipid Mediators, 2006, 79, 278-286.	1.0	47
92	The functional PDGFÎ² receptorâ€“S1P1 receptor signaling complex is involved in regulating migration of mouse embryonic fibroblasts in response to platelet derived growth factor. Prostaglandins and Other Lipid Mediators, 2006, 80, 74-80.	1.0	29
93	Cell migration activated by plateletâ€derived growth factor receptor is blocked by an inverse agonist of the sphingosine 1â€phosphate receptorâ€1. FASEB Journal, 2006, 20, 509-511.	0.2	77
94	Lipid phosphate phosphatases and lipid phosphate signalling. Biochemical Society Transactions, 2005, 33, 1370.	1.6	87
95	Regulation of cell survival by lipid phosphate phosphatases involves the modulation of intracellular phosphatidic acid and sphingosine 1-phosphate pools. Biochemical Journal, 2005, 391, 25-32.	1.7	68
96	c-Src is involved in regulating signal transmission from PDGFÎ² receptorâ€“GPCR(s) complexes in mammalian cells. Cellular Signalling, 2005, 17, 263-277.	1.7	77
97	Cellular Signaling by Sphingosine and Sphingosine 1-Phosphate. , 2004, , 245-268.		27
98	Experimental Systems for Studying the Role of G-Protein-Coupled Receptors in Receptor Tyrosine Kinase Signal Transduction. Methods in Enzymology, 2004, 390, 451-475.	0.4	6
99	Sphingosine Kinase 1 Is an Intracellular Effector of Phosphatidic Acid. Journal of Biological Chemistry, 2004, 279, 44763-44774.	1.6	193
100	Nerve growth factor signaling involves interaction between the Trk A receptor and lysophosphatidate receptor 1 systems: nuclear translocation of the lysophosphatidate receptor 1 and Trk A receptors in pheochromocytoma 12 cells. Cellular Signalling, 2004, 16, 127-136.	1.7	75
101	The role of G-protein coupled receptors and associated proteins in receptor tyrosine kinase signal transduction. Seminars in Cell and Developmental Biology, 2004, 15, 309-323.	2.3	84
102	Introduction: biology of lysophosphatidic acid and sphingosine 1-phosphate. Seminars in Cell and Developmental Biology, 2004, 15, 455.	2.3	0
103	Lysophosphatidic acid and sphingosine 1-phosphate biology: the role of lipid phosphate phosphatases. Seminars in Cell and Developmental Biology, 2004, 15, 491-501.	2.3	74
104	Sphingosine 1-Phosphate and Platelet-derived Growth Factor (PDGF) Act via PDGFÎ² Receptor-Sphingosine 1-Phosphate Receptor Complexes in Airway Smooth Muscle Cells. Journal of Biological Chemistry, 2003, 278, 6282-6290.	1.6	131
105	norpAanditprmutants reveal roles for phospholipase C and inositol (1,4,5)- trisphosphate receptor inDrosophila melanogasterrenal function. Journal of Experimental Biology, 2003, 206, 901-911.	0.8	47
106	Receptor tyrosine kinaseâ€“GPCR signal complexes. Biochemical Society Transactions, 2003, 31, 1220-1225.	1.6	53
107	Sphingosine 1-phosphate signalling and termination at lipid phosphate receptors. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2002, 1582, 121-131.	1.2	81
108	International Union of Pharmacology. XXXIV. Lysophospholipid Receptor Nomenclature. Pharmacological Reviews, 2002, 54, 265-269.	7.1	441

#	Article	IF	Citations
109	Cellular signaling by sphingosine and sphingosine 1-phosphate. Their opposing roles in apoptosis. Sub-Cellular Biochemistry, 2002, 36, 245-68.	1.0	6
110	Nerve Growth Factor Stimulation of p42/p44 Mitogen-Activated Protein Kinase in PC12 Cells: Role of G_{i/o}, G Protein-Coupled Receptor Kinase 2, Î²-Arrestin I, and Endocytic Processing. Molecular Pharmacology, 2001, 60, 63-70.	1.0	87
111	Attenuation of G-protein coupled receptor activated p42/p44 mitogen activated protein kinase by lipid phosphate phosphatases 1,1a and 2. Biochemical Society Transactions, 2001, 29, A118-A118.	1.6	0
112	Assessment of agonism at G-protein coupled receptors by phosphatidic acid and lysophosphatidic acid in human embryonic kidney 293 cells. British Journal of Pharmacology, 2001, 134, 6-9.	2.7	30
113	G-protein-coupled Receptor Stimulation of the p42/p44 Mitogen-activated Protein Kinase Pathway Is Attenuated by Lipid Phosphate Phosphatases 1, 1a, and 2 in Human Embryonic Kidney 293 Cells. Journal of Biological Chemistry, 2001, 276, 13452-13460.	1.6	88
114	Short-Term Local Delivery of an Inhibitor of Ras Farnesyltransferase Prevents Neointima Formation In Vivo After Porcine Coronary Balloon Angioplasty. Circulation, 2001, 104, 1538-1543.	1.6	43
115	Tethering of the Platelet-derived Growth Factor Î² Receptor to G-protein-coupled Receptors. Journal of Biological Chemistry, 2001, 276, 28578-28585.	1.6	147
116	Sphingosine 1-phosphate signalling in mammalian cells. Biochemical Journal, 2000, 349, 385.	1.7	464
117	Sphingosine 1-phosphate signalling in mammalian cells. Biochemical Journal, 2000, 349, 385-402.	1.7	637
118	Ceramide-dependent regulation of p42/p44 mitogen-activated protein kinase and c-Jun N-terminal-directed protein kinase in cultured airway smooth muscle cells. Cellular Signalling, 2000, 12, 737-743.	1.7	23
119	Sphingosine 1-phosphate signalling via the endothelial differentiation gene family of G-protein-coupled receptors. , 2000, 88, 115-131.		169
120	The Platelet-Derived Growth Factor Receptor Stimulation of p42/p44 Mitogen-Activated Protein Kinase in Airway Smooth Muscle Involves a G-Protein-Mediated Tyrosine Phosphorylation of Gab1. Molecular Pharmacology, 2000, 58, 413-420.	1.0	43
121	Assessment of the Extracellular and Intracellular Actions of Sphingosine 1-phosphate by Using the p42/p44 Mitogen-Activated Protein Kinase Cascade as a Model. Cellular Signalling, 1999, 11, 349-354.	1.7	32
122	Molecular Cloning of Magnesium-Independent Type 2 Phosphatidic Acid Phosphatases from Airway Smooth Muscle. Cellular Signalling, 1999, 11, 515-522.	1.7	16
123	Sphingosine 1-phosphate stimulation of the p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle. Biochemical Journal, 1999, 338, 643.	1.7	42
124	Extracellular actions of sphingosine l-phosphate through endothelial differentiation gene products in mammalian cells: role in regulating proliferation and apoptosis. Biochemical Society Transactions, 1999, 27, 404-409.	1.6	14
125	SPHINGOSINE 1-PHOSPHATE SIGNALLING. Biochemical Society Transactions, 1999, 27, A79-A79.	1.6	1
126	Platelet-derived-growth-factor stimulation of the p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle: role of pertussis-toxin-sensitive G-proteins, c-Src tyrosine kinases and phosphoinositide 3-kinase. Biochemical Journal, 1999, 337, 171.	1.7	61

#	Article	IF	Citations
127	Platelet-derived-growth-factor stimulation of the p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle: role of pertussis-toxin-sensitive G-proteins, c-Src tyrosine kinases and phosphoinositide 3-kinase. Biochemical Journal, 1999, 337, 171-177.	1.7	127
128	Sphingosine 1-phosphate stimulation of the p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle. Biochemical Journal, 1999, 338, 643-649.	1.7	83
129	PDGF-Stimulated Cyclic AMP Formation in Airway Smooth Muscle. Cellular Signalling, 1998, 10, 363-369.	1.7	12
130	Sphingolipids as differential regulators of cellular signalling processes. Biochemical Society Transactions, 1997, 25, 549-556.	1.6	30
131	Bradykinin stimulates cAMP synthesis via mitogen-activated protein kinase-dependent regulation of cytosolic phospholipase A2 and prostaglandin E2 release in airway smooth muscle. Biochemical Journal, 1997, 328, 689-694.	1.7	46
132	40 Sphingosine 1-phosphate activation of MAP kinase â€" involvement of PI 3-kinase and protein kinase C. Biochemical Society Transactions, 1997, 25, S585-S585.	1.6	4
133	Platelet-derived Growth Factor Activates a Mammalian Ste20 Coupled Mitogen-activated Protein Kinase in Airway Smooth Muscle. Cellular Signalling, 1997, 9, 311-317.	1.7	18
134	Characterization of an extract from the leaves ofCissampelos sympodialis Eichl. on the spontaneous tone of isolated trachea. Phytotherapy Research, 1997, 11, 496-499.	2.8	19
135	The identification of DLâ€‹<i>threo</i> dihydrosphingosine and sphingosine as novel inhibitors of extracellular signalâ€regulated kinase signalling in airway smooth muscle. British Journal of Pharmacology, 1996, 119, 185-186.	2.7	6
136	The differential regulation of cyclic AMP by sphingomyelin-derived lipids and the modulation of sphingolipid-stimulated extracellular signal regulated kinase-2 in airway smooth muscle. Biochemical Journal, 1996, 315, 917-923.	1.7	57
137	Sphingomyelin-Derived Lipids Differentially Regulate the Extracellular Signal-Regulated Kinase 2 (ERK-2) and c-Jun N-Terminal Kinase (JNK) Signal Cascades in Airway Smooth Muscle. FEBS Journal, 1996, 237, 819-826.	0.2	116
138	Adenylate cyclase, cyclic AMP and extracellular-signal-regulated kinase-2 in airway smooth muscle: modulation by protein kinase C and growth serum. Biochemical Journal, 1995, 306, 723-726.	1.7	10
139	Bradykinin-stimulated phosphatidylcholine hydrolysis in airway smooth muscle: the role of Ca2+ and protein kinase C. Biochemical Journal, 1995, 311, 637-642.	1.7	23
140	Phospholipase D regulation involves extracellular calcium as a conditional requirement for subsequent stimulation by protein kinase C. Biochemical Society Transactions, 1995, 23, 199S-199S.	1.6	1
141	PKC-dependent activation of the type II adenylate cyclase in airway smooth muscle limits the bradykinin-stimulated ERK-2 pathway. Biochemical Society Transactions, 1995, 23, 200S-200S.	1.6	6
142	Bradykinin-stimulated phosphatidate and 1, 2-diacylglycerol accumulation in guinea-pig airway smooth muscle: Evidence for regulation â€˜down-streamâ€™ of phospholipases. Cellular Signalling, 1994, 6, 269-277.	1.7	9
143	Bradykinin-dependent activation of adenylate cyclase activity and cyclic AMP accumulation in tracheal smooth muscle occurs via protein kinase C-dependent and -independent pathways. Biochemical Journal, 1994, 297, 233-239.	1.7	32
144	Protein kinase C-dependent cyclic AMP formation in airway smooth muscle: the role of type II adenylate cyclase and the blockade of extracellular-signal-regulated kinase-2 (ERK-2) activation. Biochemical Journal, 1994, 304, 611-616.	1.7	36

#	Article	IF	Citations
145	G-Proteins in Airways Smooth Muscle. , 1994, , 187-213.		0
146	Cellular signal pathways in tracheal smooth muscle. Cellular Signalling, 1993, 5, 401-409.	1.7	3
147	Bradykinin stimulates phospholipase D in primary cultures of guinea-pig tracheal smooth muscle. Biochemical Pharmacology, 1993, 45, 593-603.	2.0	58
148	Differential effects of B₂ receptor antagonists upon bradykininâ€stimulated phospholipase C and D in guineaâ€pig cultured tracheal smooth muscle. British Journal of Pharmacology, 1993, 110, 477-481.	2.7	29
149	Adenylyl cyclase in lung from hypersensitive guinea pig displays increased responsiveness to guanine nucleotides and isoprenaline: The role of the G proteins Gs and Gi. Biochimica Et Biophysica Acta - Molecular Cell Research, 1993, 1176, 313-320.	1.9	16
150	Muscarinic blockade of Î²â€adrenoceptorâ€stimulated adenylyl cyclase: the role of stimulatory and inhibitory guanineâ€nucleotide binding regulatory proteins (G_s and G_i). British Journal of Pharmacology, 1992, 107, 881-887.	2.7	40
151	Phosphorylation of the spliced variant forms of the recombinant stimulatory guanine-nucleotide-binding regulatory protein (GsÎ±) by protein kinase C. Biochemical Journal, 1992, 285, 333-338.	1.7	49
152	Phosphorylation of the recombinant spliced variants of the Î±-sub-unit of the stimulatory guanine-nucleotide binding regulatory protein (Gs) by the catalytic sub-unit of protein kinase a. Biochemical and Biophysical Research Communications, 1992, 186, 1081-1086.	1.0	27
153	Multiple sources of sn-1,2-diacylglycerol in platelet-derived-growth-factor-stimulated Swiss 3T3 fibroblasts. Evidence for activation of phosphoinositidase C and phosphatidylcholine-specific phospholipase D. Biochemical Journal, 1991, 279, 559-565.	1.7	100
154	Differences in the regulation of endothelin-1- and lysophosphatidic-acid-stimulated Ins(1,4,5)P3 formation in rat-1 fibroblasts. Biochemical Journal, 1991, 280, 609-615.	1.7	50
155	Regulation of the hydrolysis of phosphatidylcholine in Swiss 3T3 cells. Biochemical Society Transactions, 1991, 19, 321-324.	1.6	15
156	Mass measurement of inositol 1,4,5-trisphosphate and <i>sn</i>-1,2-diacylglycerol in bombesin-stimulated Swiss 3T3 mouse fibroblasts. Biochemical Journal, 1990, 265, 617-620.	1.7	72
157	Regulation of bombesin-stimulated inositol 1,4,5-trisphosphate generation in Swiss 3T3 fibroblasts by a guanine-nucleotide-binding protein. Biochemical Journal, 1990, 268, 605-610.	1.7	41
158	Bombesin and platelet-derived growth factor stimulate phosphatidylcholine breakdown by a common mechanism. Biochemical Society Transactions, 1990, 18, 484-485.	1.6	1
159	Development of a novel, Ins(1,4,5)P3-specific binding assay: Its use to determine the intracellular concentration of Ins(1,4,5)P3 in unstimulated and vasopressin-stimulated rat hepatocytes. Cellular Signalling, 1989, 1, 147-156.	1.7	206
160	Mass measurement of inositol phosphates. Biochimica Et Biophysica Acta - Molecular Cell Research, 1989, 1014, 239-246.	1.9	20
161	The Ins(1,4,5)P3 binding site of bovine adrenocortical microsomes: function and regulation. Biochemical Journal, 1989, 260, 593-596.	1.7	19
162	Measurement of intracellular inositol 1,4,5-trisphosphate concentrations in unstimulated and vasopressin-stimulated rat hepatocytes using a novel inositol 1,4,5-trisphosphate-specific binding assay. Biochemical Society Transactions, 1988, 16, 991-992.	1.6	13

#	Article	IF	Citations
163	The labelling of polyphosphoinositides with [32P]Pi and the accumulation of inositol phosphates in vasopressin-stimulated hepatocytes. Biochemical Journal, 1986, 238, 491-499.	1.7	73
164	A vasopressin-like peptide in the mammalian sympathetic nervous system. Nature, 1984, 309, 258-261.	13.7	148
165	The Role of Phosphatidylinositol 4,5 Bisphosphate Breakdown in Cell-Surface Receptor Activation. Journal of Receptors and Signal Transduction, 1984, 4, 489-504.	1.2	31
166	Rapid accumulation of inositol phosphates in isolated rat superior cervical sympathetic ganglia exposed to V1-vasopressin and muscarinic cholinergic stimuli. Biochemical Journal, 1984, 221, 803-811.	1.7	230